# Pizarra — PT-pseudo_2e0346bce3b3 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2e0346bce3b3
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 3.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.01 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.1 ng/mL
  - Prostate volume: 99.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7092595 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.5 ng/mL. PI-RADS 4. PSAD 0.01. Prostate volume 99 mL. csPCa 0.71.

Vitals: weight 68 kg, height 183 cm, BMI 20.3, BP 137/71 mmHg, HR 70 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2021).

Chief complaint: Assessment driven by a previously positive prostate biopsy and a steady upward trajectory in PSA measurements.

History: A 64-year-old delivery driver initially sought evaluation for elevated PSA levels in mid-2022, leading to a biopsy that confirmed low-grade disease. Following a divorce, he resides independently, with his adult daughter serving as his main point of contact. He experiences mild lower urinary tract symptoms, scoring a 6 on the IPSS scale, and manages these without alpha-blocker therapy. A smoking history of 31 pack-years was recorded before he ceased tobacco use in 2021; COPD remains stable, requiring only PRN salbutamol. He engages in light weight-training twice weekly at home and abstains from alcohol. Recent endocrinology consultations centered on routine thyroid screening, and he reports a right knee meniscectomy performed in his early twenties that remains stable without current functional limitations. There is no report of bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: The prostate presents as symmetrically enlarged yet smooth, lacking any palpable nodules or asymmetry. General assessment shows no abnormalities; height measures 183 cm, weight 68 kg, yielding a BMI of 20.3. Vital signs record a blood pressure of 137/71 mmHg and a heart rate of 70 bpm. Bilateral lung fields are clear, and the cardiovascular examination falls within normal limits.

Patient info: delivery driver; Divorced; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Light weight-training at home, 2x/week; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.19   (95% CI 0.12-0.84)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=3.5, age=64.0, psad=0.01, dre_ord=0.0, vol=99.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=4, PSA=3.5, csPCa probability=0.71) and could not weigh the clinical context, such as the patient's prior positive biopsy status, the PSA velocity (0.63 ng/mL/yr), or the specific PSA density (0.01 ng/mL²).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested 'NO BIOPSY' with a wide uncertainty interval (0.47 +/- 0.19). This wide interval suggests the classifier is genuinely unable to distinguish between the two outcomes, which aligns with the EXPERT-PROTOCOL's finding that the panel is undetermined. Furthermore, the prior failed to account for the history of a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the existing diagnosis confirmed/progressed?".
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - to assess the context of the prior positive biopsy
laboratory panel - to fully assess PSA density and other lab markers
previous notes - to determine if the prior positive biopsy result is documented as low-grade disease.
GUIDELINE ANCHOR
The guideline search indicates that the decision depends on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
mpMRI Prostate | Date: 20 Jan 2025 | Institution: Amsterdam UMC (AMC)
PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm. Prostate volume 99.0 mL yielding a PSA density of 0.01 ng/mL/mL. csPCa predicted probability 0.7092595.

get_psa_trend
PSA trend shows a rising trajectory: 1.9 ng/mL (Jun 2022) -> 2.3 ng/mL (Apr 2023) -> 2.9 ng/mL (Mar 2024) -> 3.5 ng/mL (Jan 2025).

get_previous_notes
24 Sep 2024: PSA increase to 3.1 ng/mL recorded in March alongside a history of a previously positive biopsy. Routine laboratory panels returned within normal limits.

get_lab_results
PSA: 3.5 ng/mL (26 Dec 2024). %Free PSA: 26% (26 Dec 2024).

NOT RETRIEVED
Pathology report was not retrieved because the prompt stated it was not on file for this task.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion measuring 18 mm in the left posterior peripheral zone.
- PSA trend: Rising trajectory from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025.
- Previous notes: Context of a previously positive biopsy and a noted PSA increase to 3.1 ng/mL.

AGAINST sampling this patient now:
- MRI report: Lesion is described as focal and shows early, focal enhancement, but no explicit comparison to a previous MRI is detailed in the prose.
- Lab results: Free PSA is 26%.

WHERE THIS LEANS
The evidence points toward considering further investigation due to the combination of a PI-RADS 4 lesion and a rising PSA trend following a prior positive biopsy. This leans toward a need for re-evaluation, aligning with the guideline criterion that requires assessing lesion change and prior grade documentation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence suggests further investigation is warranted because the mpMRI shows a PI-RADS 4 lesion and the PSA has a rising trajectory from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025. Since the retrieved documents do not document the prior grade or lesion change against a previous MRI, sampling is indicated to determine if the existing diagnosis has progressed, which is the reason the biopsy would be informative.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
